Economics of new oncology drug development

Journal of Clinical Oncology

Volumn 25, Issue 2, 2007, Pages 209-216

  DiMasi, Joseph A ^a   Grabowski, Henry G ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ALEMTUZUMAB; ALFUZOSIN; ALITRETINOIN; ALTRETAMINE; AMIFOSTINE; AMINOLEVULINIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; APREPITANT; ARSENIC TRIOXIDE; AZACITIDINE; BCG VACCINE; BEVACIZUMAB; BEXAROTENE; BICALUTAMIDE; BORTEZOMIB; CAPECITABINE; CETUXIMAB; CLADRIBINE; CLOFARABINE; DENILEUKIN DIFTITOX; DOCETAXEL; DOLASETRON MESILATE; DUTASTERIDE; EPIRUBICIN; ERLOTINIB; FINASTERIDE; FLUDARABINE PHOSPHATE; FULVESTRANT; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GRANISETRON; IBRITUMOMAB TIUXETAN; IDARUBICIN; IMATINIB; IRINOTECAN; LENALIDOMIDE; LETROZOLE; LEVAMISOLE; LEXIDRONAM SAMARIUM SM 153; NAVELBINE; NELARABINE; NILUTAMIDE; NORDIHYDROGUAIARETIC ACID; ONCOSPAR; OXALIPLATIN; PACLITAXEL; PALIFERMIN; PALONOSETRON; PEMETREXED; PENTOSTATIN; PHOTOFRIN; RASBURICASE; RAZOXANE; RECOMBINANT INTERLEUKIN 2; RITUXIMAB; SORAFENIB; TEMOZOLOMIDE; TENIPOSIDE; TOPOTECAN; TOREMIFENE; TOSITUMOMAB I 131; TRASTUZUMAB; TRELSTAR DEPOT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; ZOLEDRONIC ACID;

DRUG APPROVAL; DRUG CLASSIFICATION; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HEALTH ECONOMICS; HEALTH SURVEY; ONCOLOGY; PRIORITY JOURNAL; REVIEW; UNITED STATES; DRUG COST; ECONOMICS; HUMAN; NEOPLASM; PHARMACOECONOMICS;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; DRUG COSTS; DRUG DESIGN; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; HUMANS; NEOPLASMS;

EID: 33846995628     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.0803     Document Type: Review

References (25)

1. Miller S, Parker A, Peterson C, et al: Drug Trend Report 2005. St Louis, MO, Express Scripts, 2006
2. Ricks D: Experts question costly cancer care. Newsday, June 3, 2006, p A8
3. Mitchell S: Analysis: Cancer drug pipeline on the rise. United Press International, July 12, 2006, http://www.upi.com/HealthBusiness/view.php?StoryID =20060818-034618-2296r
4. Pollack A: New drugs for cancer could soon flood the market. New York Times, June 5, 2006, p C2
5. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:141-185, 2003
6. DiMasi JA, Grabowski HG, Vernon J: R&D costs and returns by therapeutic category. Drug Inf J 38:211-223, 2004
7. DiMasi JA, Hansen RW, Grabowski HG, et al: Cost of innovation in the pharmaceutical industry. J Health Econ 10:107-142, 1991
8. DiMasi JA: Success rates for new drugs entering clinical testing in the United States. Clin Pharmacol Ther 58:1-14, 1995
9. Gosse ME, DiMasi JA, Nelson TF: Recombinant protein and therapeutic monoclonal antibody drug development in the United States: 1980-1994. Clin Pharmacol Ther 60:608-618, 1996
10. DiMasi JA: Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 69:297-307, 2001
11. Abtantes-Metz RM, Adams CP, Metz AD: Pharmaceutical development phases: A duration analysis. J Pharm Fin Econ Policy 14:19-41, 2005
12. Grabowski HG, Wang YR: The quantity and quality of worldwide new drug introductions 1982-2003. Health Aff (Millwood) 25:452-460, 2006
13. DiMasi JD, Grabowski HG: The cost of biopharmaceutical R&D: Is biotech different? Manag Dec Econ (in press)
14. Berndt ER, Cockburn IM, Grepin K: The impact of incremental innovation in pharmaceuticals: Drug utilization in original and supplemental indications. Pharmacoeconomics 24:69-86, 2006 (suppl 2)
15. DiMasi JA, Paquette C: The economics of follow-on drug R&D: Trends in entry rates and the timing of development. Pharmacoeconomics 20:11-29, 2004 (suppl 3)
16. Grabowski HG: An analysis of US international competitiveness in pharmaceuticals. Manag Dec Econ, Special Issue: 27-33, 1989
17. Shulman SR, Manocchia M: The US Orphan Drug programme: 1983-1995. Pharmacoeconomics 12:312-326, 1997
18. Grabowski HG: 2005: Increasing R&D incentives for neglected diseases: Lessons from the Orphan Drug Act, in Maskus KE, Reichman JH (eds): International Public Goods, and Transfer of Technology Under a Globalized Intellectual Property Regime. Cambridge, United Kingdom, Cambridge University Press, 2005, pp 457-480
19. Med Ad News 200 - World's Best Selling Medicines - Sales. Med Ad News 21, 2002
20. Med Ad News 200 - World's Best Selling Medicines - Sales. Med Ad News 25:22-28, 2006
21. Bank of America, Equity Research, Health Care Group: Cancer Remains Large Opportunity. NY, Bank of America, 2006, pp 18-31
22. Food and Drug Administration: Challenge and Opportunity on the Critical Path to New Medical Products. Washington, DC, US Department of Health and Human Services, 2004. http://www.fda .gov/oc/initiatives/criticalpath/whitepaper.pdf
23. Roberts TG, Lynch TJ, Chabner BA: The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision. J Clin Oncol 21:3683-3695, 2003
24. Adams CP, Brantner VV: Estimating the cost of new drug development: Is it really $802 million? Health Aff 25:420-428, 2006
25. DiMasi JA: The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics 20:1-10, 2002 (suppl 3)